The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

NCT00422058 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on body weight in adults who are obese but do not have diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 564 people

Who can join Ages 18–65 · all sexes

Timeline Started 2007-01 · est. completion 2009-04

Where 19 sites · Belgium, Czechia, Denmark, Finland, Netherlands, Spain, Sweden, United Kingdom

What this study is testing ClinicalTrials.gov NCT00422058 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.

Treatments tested

liraglutide Drug

Injected s.c. (under the skin) once daily
orlistat Drug

120 mg capsule. Administered thrice daily
placebo Drug

Injected s.c. (under the skin) once daily

Main thing measured	Mean Change From Baseline in Body Weight at Week 20
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00422058 ↗